KLRK1 and Crohn disease: Results of a randomized controlled trial for the use of an anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn’s disease have reported no major improvement, but further investigations regarding dose ranging and dose regimen are needed (37).